D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Benzinga · 10/29 11:03
D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $13 price target.